Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleRadiopharmacy & Adjunctive Medications

A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ6

Nicholas Keat, Julia Kenny, Keguan Chen, Mayca Onega, Nadia Garman, Robert J. Slack, Christine A. Parker, R. Thomas Lumbers, Will Hallett, Azeem Saleem, Jan Passchier and Pauline T. Lukey
Journal of Nuclear Medicine Technology June 2018, 46 (2) 136-143; DOI: https://doi.org/10.2967/jnmt.117.203547
Nicholas Keat
1Imanova Ltd., London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Kenny
2In Vitro In Vivo Translation, GlaxoSmithKline R&D, Ware, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keguan Chen
3Immunogenicity and Clinical Immunology, GlaxoSmithKline R&D, Upper Merion, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayca Onega
1Imanova Ltd., London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia Garman
4Clinical Operations, GlaxoSmithKline R&D, Stevenage, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Slack
5Fibrosis Discovery Performance Unit, GlaxoSmithKline R&D, Stevenage, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine A. Parker
6Clinical Imaging, GlaxoSmithKline R&D, Stevenage, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Thomas Lumbers
5Fibrosis Discovery Performance Unit, GlaxoSmithKline R&D, Stevenage, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Will Hallett
1Imanova Ltd., London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Azeem Saleem
1Imanova Ltd., London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Passchier
1Imanova Ltd., London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pauline T. Lukey
5Fibrosis Discovery Performance Unit, GlaxoSmithKline R&D, Stevenage, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    PET activity though single coronal slice for subject 1, over 6 scans (scale, 0–10 kBq/mL; mid-frame time points are shown in hours:minutes:seconds).

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Organ ROIs for subject 1. Organs are colored to match those in time–activity curves (Fig. 3).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Organ time–activity curves for subject 1.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Subject Demographic and Scan Details

    SubjectSexAge (y)Weight (kg)Scan duration (min)Injected activity (MBq)Specific activity (GBq/μmol)Injected mass (μg)
    1M4795.020414525.513.0
    2M5875.621412126.410.5
    3F5985.621313435.28.7
    4F6475.61849884.32.7
    • View popup
    TABLE 2

    Residence Times of 18F-FB-A20FMDV2 for Each Organ

    OrganSubject 1Subject 2Subject 3Subject 4Mean
    Brain0.00350.00370.00340.00470.0038
    Breasts0.00340.00270.0030
    Gallbladder0.00260.00380.00360.00630.0041
    Lower large intestine0.00720.00850.01700.00530.0095
    Small intestine0.06190.06810.05710.06330.0626
    Stomach0.02170.02080.01830.01650.0193
    Upper large intestine0.01050.01120.01170.01550.0122
    Heart contents0.00930.01110.00870.01120.0101
    Heart wall0.00650.00770.00600.00780.0070
    Kidneys0.07600.06740.05600.09830.0744
    Liver0.09280.17960.16270.20840.1609
    Lungs0.03700.03260.03600.05000.0389
    Muscle0.63350.58680.34250.41090.4934
    Red marrow0.01250.01310.00980.01150.0117
    Cortical bone0.04200.02940.02510.03970.0341
    Trabecular bone0.01170.02730.00740.02120.0169
    Spleen0.00860.01830.01180.01370.0131
    Testes0.00070.00100.0009
    Thyroid0.00090.00070.00080.00100.0008
    Urinary bladder0.34100.36490.55870.36800.4082
    Organ total1.38011.45621.34001.35591.3850
    Voided urine0.59960.62461.00010.65760.7205
    Remainder0.66050.55930.30010.62660.5346
    • Data are MBq⋅h/MBq.

    • View popup
    TABLE 3

    Absorbed and Effective Dose to Each Organ

    Organβ-absorbed dose (mGy/MBq)γ-absorbed dose (mGy/MBq)Total absorbed dose (mGy/MBq)Effective dose contribution (mSv/MBq)
    Adrenals1.01E−037.62E−038.63E−034.31E−05
    Brain3.73E−041.41E−031.79E−038.93E−06
    Breasts1.19E−032.72E−033.91E−031.96E−04
    Gallbladder wall6.11E−031.05E−021.66E−020.00E+00
    Lower large intestine wall5.63E−031.18E−021.74E−022.09E−03
    Small intestine1.13E−029.82E−032.11E−021.06E−04
    Stomach wall1.11E−027.65E−031.87E−022.25E−03
    Upper large intestine wall4.66E−039.93E−031.46E−027.30E−05
    Heart wall4.64E−035.83E−031.05E−020.00E+00
    Kidneys3.46E−021.58E−025.04E−022.52E−04
    Liver1.17E−021.16E−022.33E−021.16E−03
    Lungs5.42E−035.00E−031.04E−021.25E−03
    Muscle2.46E−035.51E−037.96E−033.98E−05
    Ovaries1.01E−031.17E−021.27E−022.54E−03
    Pancreas1.01E−038.10E−039.11E−034.56E−05
    Red marrow1.96E−035.55E−037.52E−039.02E−04
    Osteogenic cells5.32E−034.87E−031.02E−021.02E−04
    Skin1.01E−033.04E−034.05E−034.05E−05
    Spleen9.95E−038.77E−031.87E−029.36E−05
    Testes3.19E−037.37E−031.06E−020.00E+00
    Thymus1.01E−034.20E−035.21E−032.61E−05
    Thyroid5.36E−034.12E−039.47E−034.74E−04
    Urinary bladder wall1.36E−016.26E−021.98E−019.92E−03
    Uterus1.01E−031.83E−021.93E−029.64E−05
    Total body2.86E−035.48E−038.33E−030.00E+00
    Effective dose (mSv/MBq)2.17E−02

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 46 (2)
Journal of Nuclear Medicine Technology
Vol. 46, Issue 2
June 1, 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ6
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ6
Nicholas Keat, Julia Kenny, Keguan Chen, Mayca Onega, Nadia Garman, Robert J. Slack, Christine A. Parker, R. Thomas Lumbers, Will Hallett, Azeem Saleem, Jan Passchier, Pauline T. Lukey
Journal of Nuclear Medicine Technology Jun 2018, 46 (2) 136-143; DOI: 10.2967/jnmt.117.203547

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ6
Nicholas Keat, Julia Kenny, Keguan Chen, Mayca Onega, Nadia Garman, Robert J. Slack, Christine A. Parker, R. Thomas Lumbers, Will Hallett, Azeem Saleem, Jan Passchier, Pauline T. Lukey
Journal of Nuclear Medicine Technology Jun 2018, 46 (2) 136-143; DOI: 10.2967/jnmt.117.203547
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Clinical Translation of a 68Ga-Labeled Integrin {alpha}v{beta}6-Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer
  • Preclinical Development and First-in-Human Imaging of the Integrin {alpha}v{beta}6 with [18F]{alpha}v{beta}6-Binding Peptide in Metastatic Carcinoma
  • Google Scholar

More in this TOC Section

  • Assessment of Residual [99mTc]Tc-Tetrofosmin Activity in Routine Nuclear Medicine Practice at Hospital Kuala Lumpur
  • Investigation of the Importance of Applying Various Methods of Calculation in Determining the Blood-Absorbed Dose for Patients with Differentiated Thyroid Carcinoma
  • Influential Factors in the Preparation of 68Ga-DOTATATE
Show more Radiopharmacy & Adjunctive Medications

Similar Articles

Keywords

  • FTIH
  • PET
  • αvβ6
  • integrin
  • A20FMDV2
SNMMI

© 2025 SNMMI

Powered by HighWire